Incyte Announces Acquisition of Vega Therapeutics for Up to $2 Billion

Incyte has reached a definitive agreement to purchase Vega Therapeutics, a Star Therapeutics subsidiary. The deal involves an initial payment of $1.25 billion, with an additional $750 million possible based on sales milestones. This acquisition aims to enhance Incyte's hematology product line by adding VGA039, a monoclonal antibody currently in Phase 3 development.